Dorte Vistisen
Steno Diabetes Center
157 Papers
399 Citations
Dorte Vistisen is an academic researcher from Steno Diabetes Center. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 30, co-authored 120 publications. Previous affiliations of Dorte Vistisen include Novo Nordisk & University of Southern Denmark.
Chat about Author
Papers
Phenotypic Responses to a Lifestyle Intervention Do Not Account for Inter-Individual Variability in Glucose Tolerance for Individuals at High Risk of Type 2 Diabetes.
Grainne O'Donoghue,Aileen Kennedy,Gregers S. Andersen,Bernadette Carr,Stephen Cleary,Eoin Durkan,Heidi Davis,Kristine Færch,Paula Fitzpatrick,Helena Kenny,Noel McCaffrey,Javier Monedero,Enda Murphy,John Noone,Tommi Suvitaival,Tanja Thybo,Michael Wheeler,Dorte Vistisen,John J. Nolan,John J. Nolan,Donal J. O’Gorman +20 more
TL;DR: It is found that phenotypic characteristics from standard clinical and physiological parameters were not sufficient to account for the inter-individual variability in glucose tolerance following a 12 weeks lifestyle intervention in inidivuals at high risk for type 2 diabetes.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Dorte Vistisen,Bendix Carstensen,Patorno E Elisabetta,Stefanie Lanzinger,Elise Chia-Hui Tan,Daisuke Yabe,Dae Jung Kim,Wayne H-H Sheu,Cheli Melzer-Cohen,Reinhard W. Holl,J. Núñez,Kyoung Hwa Ha,Sigrun Halvorsen,Gisle Langslet,Avraham Karasik,Thomas Nyström,Leo Niskanen,Sonia Guleria,Riho Klement,Marc Carrasco,Johannes Foersch,Christina Shay,Lisette Koeneman,Fabian Hoti,Soulmaz Fazeli Farsani,Kamlesh Khunti,Francesco Zaccardi,Anuradha Subramanian,Krishnarajah Nirantharakumar,Kimberly G. Brodovicz,Kristina Zint,Johannes Försch,Doron Rosenzweig,Maria Lajer,M. Overgaard,Emilie Toresson Grip,Emma Söreskog,J Gunnarsson,Kristina Karlsdotter,L. Stenman,M. Tuovinen,N. Valveny,Paula Casajust,R. Farmer,A. Ternouth,Anne Pernille Ofstad,Masaomi Koichi Yusuke Atsutaka Yutaka Jingbo Weiyu Sunwoo Nangaku Node Taneda Yasui Seino Yi Lei Lee Lee,Masaomi Nangaku,Koichi Node,Yusuke Taneda,Atsutaka Yasui,Yutaka Seino,Jingbo Yi,Weiyu Lei,Sunwoo Lee,Jinhee Lee +55 more
TL;DR: Empagliflozin reduces cardiovascular risk compared to dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease, with lower rates of heart failure, mortality, and stroke observed in patients initiating empagliflozin in routine care settings across Europe and Asia.
Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Gisle Langslet,Thomas Nyström,Dorte Vistisen,Bendix Carstensen,Emilie Toresson Grip,Paula Casajust,Giorgi Tskhvarashvili,Fabian Hoti,Riho Klement,Kristina Karlsdotter,M. Tuovinen,Anne Pernille Ofstad,Maria Lajer,Christina Shay,Lisette Koeneman,Soulmaz Fazeli Farsani,Leo Niskanen,Sigrun Halvorsen +17 more
TL;DR: Empagliflozin significantly reduces all-cause mortality, hospitalization for heart failure, cardiovascular mortality, and end-stage renal disease by 49%, 36%, 52%, and 66% respectively, compared to DPP-4i in Nordic type 2 diabetes patients, with no significant difference in stroke and myocardial infarction risk.
Trajectories of body mass index before the diagnosis of cardiovascular disease: a latent class trajectory analysis.
Klodian Dhana,Joost van Rosmalen,Dorte Vistisen,M. Arfan Ikram,Albert Hofman,Albert Hofman,Oscar H. Franco,Maryam Kavousi +7 more
TL;DR: The majority of individuals who developed CVD had a stable weight during follow-up, suggesting that BMI alone is not a good indicator for identifying middle-aged and elderly individuals at high risk of CVD.
High and low vitamin D level is associated with cardiovascular autonomic neuropathy in people with Type 1 and Type 2 diabetes
Christian Stevns Hansen,Jesper Fleischer,Dorte Vistisen,Martin Ridderstråle,Jan Skov Jensen,Marit E. Jørgensen +5 more
TL;DR: To investigate the possible association between vitamin D deficiency and cardiovascular autonomic neuropathy in people with diabetes, a large number of patients with diabetes are treated with vitamin D antagonists.